POL196 - Deceased Donor Liver Distribution and Allocation

What this platform has drawn from it — 5 claims

• In the UK, elective liver transplant patients with chronic liver disease, hepatocellular carcinoma, or a diuretic-resistant ascites or chronic hepatic encephalopathy indication are prioritised for offering according to their Transplant Benefit Score. Section 4.3.1, p. 15
  held in the ledger, not rendered on any page
• The Transplant Benefit Score integrates a patient's expected survival without a transplant with their expected survival after transplantation with the graft on offer, and is the difference between expected utility from the transplant and predicted need; the patient with the greatest difference scores highest. Sections 4.3.1 and 4.3.2, pp. 15-16
  held in the ledger, not rendered on any page
• The Transplant Benefit Score is calculated for each eligible patient and each donor offer using 16 recipient characteristics and 6 donor characteristics. Section 4.3.1 and Table 1, pp. 15-16
  held in the ledger, not rendered on any page
• Patients registered with a variant syndrome are prioritised by waiting time rather than by Transplant Benefit Score, and a proportional offering rule randomly selects between the chronic liver disease and hepatocellular carcinoma list and the variant syndrome list, with a 90% probability of selecting the former and 10% the latter. Sections 4.3.4 and 4.3.6, p. 16
  held in the ledger, not rendered on any page
• Only patients whose weight is within 20 kg of the donor's weight are included in a Transplant Benefit Score based offering sequence, and within 10 kg for variant syndrome offering sequences. Sections 4.3.3 and 4.3.4, p. 16
  held in the ledger, not rendered on any page